Table 1.

Characteristics of included studies.

Study no.	Publication	Type	No.	MBCT duration	Follow-up	Location	Agesa	Patients	Experimental group	Control groups	Primary outcomes	Secondary outcomes
1	Teasdale et al., 2000, 2002; Williams et al., 2000, 2008	RCT multi-center	145	8 weeks	1 yr	Great Britain, Canada	18–65	Patients with MD (≥2 episodes) in remission	MBCT + TAU	TAU	Relapse that meets DSM-III criteria for MD	BDI II, MACAM, use of AD, type of memory
2	Ma and Teasdale, 2004; Williams et al., 2008	RCT	75	8 weeks	1 yr	Great Britain	18–65	Patients with (≥MD 2 episodes) in remission	MBCT + TAU	TAU	Relapse that meets DSM-III –R criteria for MD	BDI II
3	Kuyken et al., 2008	RCT	123	8 weeks	1 yr	Great Britain	≥18	Patients with MD (≥3 episodes) in remission, taking ADs	MBCT +support to discontinue or reduce ADs	Maintenance ADs	Relapse that meets DSM-III criteria for MD	Characteristics of relapses, BDI II, HAM-D, psychiatric co-morbidities, WHOQOL-BREF, cost
4	Barnhofer et al., 2007; Crane et al., 2008; Hepburn et al., 2009; Williams et al., 2008	RCT	68	8 weeks	1 yr	Great Britain	18–65	Bipolar and unipolar patients with MD (≥1 episode) in remission with suicidal ideation	MBCT + TAU	TAU	Prefrontal alpha-asymmetry during sleep EEG, BDI II, BAI, White Bear Suppression Inventory
5	Godfrin and van Heeringen, 2010	RCT	106	8 weeks	1 yr	Belgium	≥18	Patients with MD (≥3 episodes) in remission	MBCT + TAU	TAU	Relapse that meets DSM-IV-TR criteria for MD	BDI II, HAM-D, POMS, QLDS
6	Bondolfi et al., 2010	RCT	60	8 weeks	1 yr	Switzerland	18–65	Patients with MD (≥3 episodes) in remission	MBCT + TAU	TAU	Relapse that meets DSM-IV criteria for MD	BDI II, frequency of practice of full attention during the study
7	Barnhofer et al., 2009; Hargus et al., 2010	RCT	31	8 weeks	absent	Great Britain	18–65	Patients with MD (≥3 episodes) with suicidal ideation	MBCT + TAU	TAU	Relapse that meets DSM-IV criteria for MD	BDI II and Beck scale for sucicidal ideation
8	Foley et al., 2010	RCT	115	8 weeks	12 weeks	Australia	≥18	Oncology patients with depression	MBCT + TAU	TAU	HAM-D, HAM-A, DASS, (FACT–G)	Frieburg Mindfulness Inventory
9	Piet et al., 2010	RCT crossover	26	8 weeks	1 yr	Denmark	18–25	Patients with social phobia	MBCT	GCBT	LSAS, SPS and SIAS	SPC,SCL-90-R, Symptom Checklist- 90-Revised, IPP, FNE, SDS, BDI II, BAI
10	Britton et al., 2010; Shahar et al., 2010	RCT	26	8 weeks	absent	USA	24–64	Antidepressant-free individuals with partial or totally remission of DM (≥3 episodes), with residual sleep complaints	MBCT + TAU	TAU	Polysomnographic sleep profiles	BDI II, sleep diaries
11	Segal et al., 2010	RCT	84	8 weeks	18 months	Canada	18–65	Patients with MD (≥2 episodes) in remission	MBCT + support to discontinue ADs	2 groups: Placebo and maintenance ADs	Time to relapse/recurrence of DM	–

^aMale and female patients.

Yr: year; RCT: randomised controlled trial; MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; DM: major depression; BDI: Beck depression inventory; MACAM: measure of awareness and coping in autobiographical memory; AD: antidepressants; HAM-D: Hamilton rating scale for depression; WHOQOL-BREF: World Health Organization Quality of Life instrument; EEG: electroencephalogram; BAI: Beck anxiety inventory; POMS: profile of moods scale; QLDS: quality of life in depression scale; HAM-A: Hamilton anxiety rating scale; DASS: depression, anxiety stress scale; FACT-G: functional assessment of cancer therapy-general; GCBT: group cognitive-behavioural therapy; SPC: social phobia composite; SPS: social phobia scale; SIAS: social interaction scale; LSAS: Liebowitz social anxiety scale; SCL-90-R: symptom checklist-90-revised; IPP: inventory of interpersonal problems; FNE: fear of negative evaluation; SDS: Shehan disability scale.